fbpx

Clinical Trials

25 results.

June 13, 2017 VARI-SU2C Epigenetics Dream Team launches new clinical trial to combat blood cancers

International collaboration pairs immunotherapy with an epigenetic drug to stop progression of chronic myelomonocytic leukemia and myelodysplastic syndrome into acute myeloid leukemia GRAND RAPIDS, Mich.…

May 15, 2017 VARI cancer researcher elected to National Academy of Sciences

Stephen Baylin becomes third VARI-affiliated scientist to attain the distinction GRAND RAPIDS, Mich. (May 15, 2017) — Stephen Baylin, M.D., Director’s…

March 7, 2017 New drug combination targets aggressive blood cancer

Safety and efficacy of combining talazoparib with decitabine to treat acute myeloid leukemia (AML) are subject of multi-site clinical trial GRAND RAPIDS, Mich. (March 7,…

December 30, 2016 What difference does a year make?

When it comes to biomedical research and science education, a year can make all the difference. In 2016, we celebrated Van Andel…

December 8, 2016 New hope for Parkinson’s disease

By: Patrik Brundin, M.D., Ph.D. Director of Van Andel Research Institute’s Center for Neurodegenerative Science, chairman of The Cure Parkinson’s Trust’s Linked…

December 7, 2016 Diabetes drug slows experimental Parkinson’s disease progression, human trials to begin next year

New data published today shows drug preserves critical brain function in laboratory models of Parkinson’s GRAND RAPIDS, Mich. (Dec. 7, 2016)—A new investigational drug originally…

VAI DEFAULT HEADER
September 8, 2016 Diabetes drug focus of new clinical trial for Parkinson’s disease

HIGHLIGHTS A clinical trial is now underway at Cedars-Sinai in Los Angeles to test the efficacy and safety of a type II diabetes drug as…

VAI DEFAULT HEADER
February 22, 2016 Promising respiratory drug focus of new clinical trial for Parkinson’s disease

GRAND RAPIDS, Mich. (February 22, 2016)—A medication approved to treat various respiratory diseases and that has demonstrated neuroprotective effects in preclinical studies is the focus…